ARS Pharma Says U.K. MHRA Grants Approval For EURneffy For Emergency Treatment Of Allergic Reactions In Adults And Children Who Weigh Greater Than 30 Kg

+1.02%

+0.66%

Alaska Air Group, Inc.

ALK

52.42

+1.02%

ARS Pharmaceuticals, Inc. - Common Stock

SPRY

10.66

+0.66%

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025

U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh greater than 30 kg.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.